These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Validity and limits of invasive pharmacological tests in the treatment of malignant ventricular hyperkinetic arrhythmias]. Disertori M; Vergara G; Inama G; Guarnerio M; Furlanello F; Botti G; Bonatti V; Rolli A G Ital Cardiol; 1983; 13(4):311-4. PubMed ID: 6884675 [TBL] [Abstract][Full Text] [Related]
6. Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia. Yeung-Lai-Wah JA; Murdock CJ; Boone J; Kerr CR J Am Coll Cardiol; 1992 Sep; 20(3):547-51. PubMed ID: 1512331 [TBL] [Abstract][Full Text] [Related]
7. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Coumel P; Leclercq JF; Assayag P Am J Cardiol; 1984 Nov; 54(9):60D-66D. PubMed ID: 6208770 [TBL] [Abstract][Full Text] [Related]
8. [Value of a serial electropharmacologic study in survivors of a cardiac arrest secondary to ventricular tachycardia or ventricular fibrillation]. Raviele A; Di Pede F; Delise P; Piccolo E G Ital Cardiol; 1984 Sep; 14(9):644-54. PubMed ID: 6510619 [TBL] [Abstract][Full Text] [Related]
9. Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. Brodsky MA; Allen BJ; Abate D; Henry WL Am Heart J; 1985 Oct; 110(4):794-9. PubMed ID: 4050651 [TBL] [Abstract][Full Text] [Related]
11. Serial electrophysiological testing of antiarrhythmic drug efficacy in patients with recurrent ventricular tachycardia. Breithardt G; Seipel L; Abendroth RR; Loogen F Eur Heart J; 1980 Feb; 1(1):11-24. PubMed ID: 7026245 [No Abstract] [Full Text] [Related]
12. Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone. Stavens CS; McGovern B; Garan H; Ruskin JN Am Heart J; 1985 Jul; 110(1 Pt 1):24-9. PubMed ID: 4013986 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of recurrent ventricular tachycardias using oral propafenone]. Cointe R; Lévy S; Metge M; Vrancea F; Labrunie P; Valeix B; Gérard R Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():59-62. PubMed ID: 3938260 [TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. Chilson DA; Heger JJ; Zipes DP; Browne KF; Prystowsky EN J Am Coll Cardiol; 1985 Jun; 5(6):1407-13. PubMed ID: 3889099 [TBL] [Abstract][Full Text] [Related]
15. The treatment of ventricular tachycardia using an automatic tachycardia terminating pacemaker. Griffin JC; Mason JW; Ross DL; Calfee RV Pacing Clin Electrophysiol; 1981 Sep; 4(5):582-8. PubMed ID: 6169047 [TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. Shen EN; Sung RJ; Morady F; Schwartz AB; Scheinman MM; DiCarlo L; Shapiro W J Am Coll Cardiol; 1984 May; 3(5):1291-7. PubMed ID: 6707382 [TBL] [Abstract][Full Text] [Related]
17. Tachyarrhythmias. Application of new information to clinical management. Saksena S; Gadhoke A Postgrad Med; 1986 Jun; 79(8):121-36. PubMed ID: 3520521 [TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic and electrophysiologic effects of oral propafenone. Prystowsky EN; Heger JJ; Chilson DA; Miles WM; Hubbard J; Zipes DP Am J Cardiol; 1984 Nov; 54(9):26D-28D. PubMed ID: 6496366 [TBL] [Abstract][Full Text] [Related]
19. [The value of antitachycardia pacemaker therapy in patients with Wolff-Parkinson-White syndrome]. Neumann G; Grube E; Funke H Herz; 1983 Jun; 8(3):153-64. PubMed ID: 6873862 [No Abstract] [Full Text] [Related]
20. Termination of ventricular tachycardia by programmed extrastimuli from an externally-activated permanent pacemaker. Greene HL; Gross BW; Preston TA; Werner JA; Kime GM; Hessel EA; Weaver WD; Duncan JL Pacing Clin Electrophysiol; 1982 May; 5(3):434-9. PubMed ID: 6179061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]